Form 8-K - Current report:
SEC Accession No. 0001140361-21-019927
Filing Date
2021-06-04
Accepted
2021-06-04 16:48:36
Documents
7
Period of Report
2021-06-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K nt10025479x1_8k.htm 8-K 24700
2 EXHIBIT 1.1 nt10025479x1_ex1-1.htm EX-1.1 40385
3 EXHIBIT 4.1 nt10025479x1_ex4-1.htm EX-4.1 88524
4 EXHIBIT 5.1 nt10025479x1_ex5-1.htm EX-5.1 17022
5 EXHIBIT 10.1 nt10025479x1_ex10-1.htm EX-10.1 251429
6 EXHIBIT 99.1 nt10025479x1_ex99-1.htm EX-99.1 10026
7 nt10025479x1_ex5-1image0.jpg GRAPHIC 109196
  Complete submission text file 0001140361-21-019927.txt   583929
Mailing Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335
Business Address 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335 248-681-9815
Ocuphire Pharma, Inc. (Filer) CIK: 0001228627 (see all company filings)

EIN.: 113516358 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34079 | Film No.: 21997095
SIC: 2834 Pharmaceutical Preparations